Zevra Therapeutics (NASDAQ:ZVRA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.20) by 70 percent. This is a 85 percent increase over losses of $(0.40) per share from the same period last year. The company reported quarterly sales of $20.40 million which beat the analyst consensus estimate of $16.96 million by 20.30 percent. This is a 495.65 percent increase over sales of $3.42 million the same period last year.